Company Number 05766541
Charity Number 1122484

European Society for Paediatric Endocrinology

Company Limited by Guarantee

Annual Report

31 December 2025

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

FINANCIAL STATEMENTS

YEAR ENDED 31 DECEMBER 2025

CONTENTS **PAGE**

TRUSTEES' ANNUAL REPORT	1
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY	21
STATEMENT OF FINANCIAL ACTIVITIES	24
BALANCE SHEET	25
STATEMENT OF CASH FLOWS	26
NOTES TO THE FINANCIAL STATEMENTS	27
MANAGEMENT INFORMATION	37
DETAILED PROFIT AND LOSS ACCOUNT	38

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees have pleasure in presenting their report and the financial statements of the charitable company for the year ended 31 December 2025.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered charity name	European Society for Paediatric Endocrinology
Charity registration number	1122484
Company registration number	05766541
Registered office	RWK Goodman 69 Carter Lane London EC4V 5EQ

THE TRUSTEES

The trustees who served the charitable company during the year and up to the date of this report were as follows:

Professor I. Banerjee
Professor S. Cianfarani
Professor M. Dattani
Professor P. Kühnen
Professor M. Maghnie
Professor R. Verkauskiene
Dr E. Gevers (Appointed 1 April 2025)
Professor Dr V. Iotova (Appointed 9 September 2025)
Professor M. Cools (Resigned 1 April 2025)
Professor R. Hamza (Resigned 9 September 2025)
Professor A. Hokken-Koelega (Resigned 9 September 2025)

Auditor	Crowe U.K. LLP 3rd floor St George's House 56 Peter Street Manchester M2 3NQ

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

PRESIDENTS' REPORT

WELCOME

Dear ESPE Members and Colleagues,

It is my great privilege to welcome you to the ESPE Annual Report. I began my term as ESPE President in September 2025, and I am honoured to represent such a vibrant and dedicated community committed to advancing paediatric endocrinology. This past year has been marked by remarkable energy and collaboration across our committees, working groups, and membership, reflecting our shared purpose and determination to improve the lives of children affected by endocrine disorders.

Our society has made significant progress, from strategic planning and the development of educational programmes to sustained advocacy efforts. We have fostered meaningful partnerships with other paediatric endocrinology societies worldwide, supporting education, training, and research to deliver the highest standards of care. ESPE's commitment to innovation is evident in initiatives like our ESPE Connect webinars, joint events with ESE and Endo-ERN, and the launch of the ESPE Bone Academy, each providing invaluable opportunities for learning, collaboration, and professional growth.

This report highlights our achievements, ongoing projects, and future ambitions. I am grateful for the dedication shown by our members and encourage you to make the most of the opportunities ESPE offers, whether through committee participation, educational events, or networking with colleagues. Together, we continue to ensure that ESPE thrives and evolves, setting the benchmark for excellence in paediatric endocrinology.

Thank you for your commitment and enthusiasm. I would particularly like to give thanks to ESPE Past President Anita Hokken-Koelega, who stepped down from her role in early September 2025, at the end of her second and final term of office. An extraordinary leader, Anita's tenure as President has been marked by her unwavering dedication, leadership, and a profound commitment to ESPE's mission.

I look forward to working with you all as we build on this momentum to deliver lasting impact in our field.
With warmest regards,

Professor Mehul Dattani
ESPE President

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

INTRODUCTION

The European Society for Paediatric Endocrinology ("The Society" and "ESPE") is a charity and a company limited by guarantee. Its members are clinicians and researchers with an involvement in paediatric endocrinology. The Society's beneficiaries are its members (who are largely clinical paediatric endocrinologists or allied health professionals), students, paediatric endocrine patients, and the general public. The Society provides a range of public benefits aimed at providing educational and research support to these groups and the activities to deliver these benefits are detailed in this report for the period 1 January to 31 December 2025.

The principal activity of the Society is to promote knowledge of paediatric endocrinology in the widest sense to the widest possible audience in order to improve patient care. It does so by organising an annual scientific meeting, a programme of educational and training Schools and Academies, hosting a eLearning platform which is freely available and also webinar series for personal communication and knowledge transfer on subjects of paediatric endocrinology. These activities are either free to attend or supported by an ESPE grants and fellowships portfolio. All activities aim to further research and education in paediatric endocrinology by bringing together people with an active interest in our specialty, by arranging exchange visits of members and their collaborators, by promoting joint projects and by other means desired by the Society. The Society also stimulates contacts with other societies with like aims.

PUBLIC BENEFIT

The Society benefits the public through the provision of education, training, guidance and research evidence to support healthcare professionals to implement the best, evidence-led clinical practice for paediatric patients, their families and the public more broadly.

Paediatric endocrinology is a specialty of children's medicine (paediatrics) caring for babies, children and adolescents with growth, puberty, sexual development problems and other disorders of the hormone producing glands of the body. These include diabetes, thyroid and adrenal gland problems, early and late puberty, bone conditions and growth hormone deficiency.

Specifically, we provide:

- Research funding to support the advancement of scientific and medical research in paediatric endocrinology
- Support for fellowships and attendance at our Schools and Academies
- Organised educational and training events for healthcare professionals to ensure the highest standards in a key area of public health
- Support for the publication of an international journal
- The formation of an accessible network of experts in the field of paediatric endocrinology
- Clinical guidelines and guidance, patient booklets, summaries and patient-accessible documents
- A quarterly newsletter, ESPE News, for the paediatric endocrinology community
- An annual Yearbook of Paediatric Endocrinology which summarises and comments on the major advances in paediatric endocrinology during the previous year.

This report demonstrates how the Society's charitable funds for the reported year were distributed and spent, and the benefits and impact of this on the advancement of medical research and clinical practice. The Society has referred to the Charity Commission's guidance on public benefit when reviewing its aims and objectives and in planning for future activities. The Trustees confirm that ESPE has complied with its duty to have regard for the guidance on public benefit published by the Charity Commission on exercising its powers and duties.

STRUCTURE, GOVERNANCE AND MANAGEMENT

History and purpose

In 1962, following attendance to the 4th Acta Endocrinologica Congress in Geneva, Professor Andrea Prader invited 26 paediatricians and endocrinologists with an interest in foetal and paediatric issues to attend an informal post conference meeting and so the first 'Paediatric Endocrinology Club' was formed. These meetings provided young European Investigators with a platform to discuss Paediatric

Endocrinology in-depth. ESPE was officially founded at the meeting in Copenhagen in 1965, with the mission 'The Society shall promote knowledge of Paediatric Endocrinology in the widest Sense'.

The Society is also actively involved in promoting the interests of the general public and in advising on European health policy in the area of paediatric endocrinology. ESPE is also a founding member of the International Consortium of Pediatric Endocrinology (ICPE), which exists to foster global collaboration in paediatric endocrinology. The European Commission has officially designated ESPE as the body responsible for organising and monitoring training in paediatric endocrinology.

The aims of the Society are as stated in the objectives and activities section. All funds generated are used to support projects in pursuance of these aims, such as grants to early career scientists, educational activities, creation and publication of clinical guidelines and guidance, a website and a newsletter which is available to the public free via the website as well as being disseminated to members.

In 2006, ESPE transitioned from an unincorporated organisation to a Private Company limited by guarantee, registered in England & Wales (Company No: 5766541) and a Registered Charity in 2008 (Charity No: 1122484).

These accounts have been audited as a charitable organisation.

Membership

The Society has the following categories of membership:

1) Clinician Members: Full; Early Career, Student or Retired;
2) Scientist Members: Full; Early Career; Student or Retired;
3) Nurse Members: Full; Early Career; Student or Retired;
4) Allied Health Professional Members: Full; Mid-Career; Early Career; Student or Retired.

The membership categories were reviewed and restructured in 2021 to provide additional insight into the members of the Society and to enable future strategic planning. Details of eligibility criteria and fees for each categwory are outlined on the Society's website. All applications for membership are reviewed and approved in accordance with eligibility and the ESPE Sanctions policy.

Governing body

ESPE Council is the Society's governing body. ESPE Council consists of not less than eight and not more than twelve members, including the President, the Chairs of the Finance and Strategic Committee, Chair of the Corporate Liaison Board, Clinical Practice Committee, Programme Organising Committee, Education and Training Committee, Communication Committee, and Science Committee, and the Annual Meeting Host. All serve as Directors and Trustees with the exception of the Annual Meeting Host. In accordance with the ESPE byelaws, Council may appoint up to two more *ex-officio* members provided the total number on the Council does not exceed ten. *Ex-officio* Council members have no vote and are not directors of the Society. Any individual Voting Member who is in good standing with his or her membership subscription is eligible to stand for election to Council. A Voting Member may nominate himself or herself.

All members of Council other than the President serve a term of three years. The President serves as an *ex-officio* member of Council during the year preceding their first term of office.

The President and the Chairs of committees are eligible to extend their first term of office by one year or to stand for re-election for one further term of three years. If Council members choose to extend their first term of office by one year they are not eligible for re-election for a second term of office thereafter. Council members other than the President and Committee chairs are not eligible for re-election except to the position of President, or as a committee chair.

Committees

The Society has had seven Council Committees, which report to the ESPE Council through their Chair. The appointment of the committee chairs and definition of their remit is the responsibility of ESPE Council.

Committee	Responsibilities
Strategic and Finance Committee	Financial planning, budgets, accounts and investments
Clinical Practice Committee	Undertakes projects to maintain and improve clinical practice standards in paediatric endocrinology
Programme Organising Committee	Scientific programme of the Annual Scientific Meeting
Education and Training Committee	Maintaining and improving education and training for paediatric endocrinologists
Corporate Liaison Board	Establishing and maintaining relationships with industry representatives
Communication Committee	Developing the Society's communication strategy
Science Committee	Scientific collaboration, scientific networking, ESPE support of projects and the administration of various grants and fellowships, including the ESPE Research Unit, Research Fellowship, Early Career Scientific Development Grant and Scientific Career Development Grant

In addition to the Chair, each committee has three or more additional members recruited via an open call to ESPE members proposed by the Committee and approved by Council.

The Council delegates certain responsibilities out to other sub-committees or steering groups to organise the following: travel grants; Clinical Fellowships; eLearning; the policy and advocacy program; the rare disease activities; the allocation of prizes and awards; ESPE Schools and Academies; the development and update to the training and training syllabus in paediatric endocrinology, the editorship of their newsletter and website; and the ESPE Paediatric Endocrinology Training Centres for Africa (PETCA) programme.

The Young ESPE (YES) Group is a dynamic group of early career ESPE members that aims to create a space for young paediatric endocrinologists, so that they can share expertise and grow their careers through access to professional development, collaboration and research opportunities.

What does the YES Group do?

- Represents early career members within specific ESPE committees
- Organises educational and networking events
- Collaborates with similar early career groups
- Provides mentorship opportunities for members
- Keeps members up to date with the latest career opportunities

ESPE provides a platform for our members to form special interest working groups which work in specific aspects of paediatric endocrinology. At the time of writing our special interest groups are:

- Working Group on Difference of Sex Development
- Working Group on Gender Incongruence
- Working Group on Obesity
- Working Group on Bone and Growth Plate
- Working Group on Turner Syndrome
- Working Group on Paediatric Endocrine Nurses
- Working Group on Paediatric and Adolescent Gynaecology
- Working Group on Thyroid

How we raise funds
The Society raises its funds mainly through income from its annual scientific meeting and membership subscriptions. The Society also receives pharmaceutical support through sponsorship of certain educational and research activities. The Society is immensely grateful for this support.

OBJECTIVES AND ACTIVITIES

The objects of the Society are to promote for the public benefit research, education and clinical practice in paediatric endocrinology by the organisation of conferences, educational activities and publications, by making grants, by raising public awareness, liaison with national and international legislators, and by any other appropriate means.

Major areas of activity in support of these objectives

Conferences
The Society runs an annual ESPE Meeting, which regularly attracts around 4,000 basic scientists and clinicians from throughout the world. The research and clinical practice presented at the congress aims to improve scientific research and clinical practice for patients. The ESPE Meeting is recognised worldwide as a meeting of high scientific and educational quality. It takes place in a different European city each year.

In addition, every four years ESPE collaborates with the other regional societies around the world specialising in paediatric endocrinology to contribute to the organisation of the International Meeting of Paediatric Endocrinology (IMPE), under the banner of the International Consortium of Paediatric Endocrinology (ICPE). The latest meeting took place in 2023 in Buenos Aires, Argentina, with the next meeting scheduled to be held in Japan 2027.

In 2025 the ESPE Annual Meeting was organised as a joint Congress with the European Society of Endocrinology (ESE), and took place in Copenhagen in May 2025. The major areas of interest were Adrenal and Cardiovascular Endocrinology, Bone and Mineral Metabolism, Diabetes and Insulin, Endocrine-related Cancer, Environmental Endocrinology, Fetal and Neonatal Endocrinology, Growth Axis and Syndromes, Metabolism, Nutrition and Obesity, Multisystem Endocrine Disorders, Pituitary, Neuroendocrinology and Puberty, Reproductive and Developmental Endocrinology and Thyroid.

The joint event marked a record-breaking year, attracting 7,832 attendees across in-person and online participation. It also received 3,334 abstract submissions, 45% of which focused on paediatric, transition, or themes across the lifecourse. A second joint event is planned for 2029.

Education and Training
Training in paediatric endocrinology is an important priority for the Society. The Society is officially designated by the European Commission as the body responsible for organising and monitoring training in paediatric endocrinology. To this end, numerous educational programmes are sponsored by the Society in order to offer the most up-to-date and efficient training in paediatric endocrinology.

The Education and Training Committee (ETC) is proactively working to provide structured means of accreditation for Training Centres in Paediatric Endocrinology in Europe. In addition, electronic education and training are among the Society's top priorities. The Society has invested in an e-learning web portal, which was redeveloped in 2025 and re-launched in 2026 under the remit of the E-Learning Committee.

This e-learning platform gives members and other registrants entrance to an interactive learning environment for up-to-date paediatric endocrinology.

In 2007 the Society initiated a programme for paediatric training in developing countries (PETCA), working initially with three paediatric departments in Nairobi and Kenya. Students from a number of sub-Saharan countries continue to graduate from the Nairobi centre and a second PETCA has been established in Lagos, Nigeria. Graduates from PETCA have now also established the African Society for Paediatric and Adolescent Endocrinology. ESPE is slowly withdrawing from this project, whilst maintaining an overview and continuing to provide funding to fellows, to enable the programme to run independently in the future.

ESPE Schools
The Society regularly runs five schools which support paediatricians who have entirely or partially completed their basic paediatric training and who are now either established in, or intending to develop a deep and continuing interest in, paediatric endocrinology.

The Summer, Winter and the Diabetes, Obesity and Metabolism (DOM) schools are designed for those in training who have entirely or partially completed their paediatric training and who are established in the field or intend to develop their career in paediatric endocrinology with the DOM School looking at further specialising in diabetes, obesity and metabolism.

The ESPE Maghreb School promotes the training and education of paediatric endocrinologists in French-speaking North African countries.

A Caucasus and Central Asia School, which is conducted in both Russian and English, runs a successful in-person event, proactively assessing security and safety when near any countries of unrest.

ESPE Academies
ESPE also runs a joint academy with the Arab Society for Paediatric Endocrinology and Diabetes which is running successfully.

During 2025, Council approved the development and delivery of two new academies: the Bone Academy and the Leadership Academy, both of which will take place in 2026.

ESPE Connect Webinar series
The ESPE Connect Webinar Series runs successful webinar series which is attended by both ESPE members and non-members. The series is designed to offer highly targeted content through webinars on a variety of subjects and are free to attend.

ESPE Science Symposia
A biennial ESPE Science Symposium was initiated in 2017 to help disseminate the latest scientific knowledge and close the gap between research and patients. The Science Symposia now take place annually.

Clinical Practice
The Society, through the Clinical Practice Committee (CPC), focuses on the agreement of consensus statements and the publication of guidelines to guide and standardise the child healthcare system and/or improve the health of children with endocrine disease in Europe. The CPC is also responsible for ESPE's public and patient information and is in the process of updating its information leaflets for patients with endocrine conditions.

Support of science, research and professional development through awards and fellowships
The Society gives various awards and fellowships supporting its members in their clinical practice and research. In 2025 there were six awards agreed in recognition of outstanding teaching, research and contribution to paediatric endocrinology, namely: the Andrea Prader Prize; the Research Award; two ESPE Young Investigator Awards; the International Outstanding Clinician Award and the ESPE International Research Award.

In addition, the Society offers opportunities for both early career and senior members who are intent on building up a scientific, research and clinical career in paediatric endocrinology by providing the following: ESPE Research Fellowship; ESPE Clinical Fellowship; ESPE Early Career Scientific Development Grant (formerly the Early Career Scientific Development Award); Henning Andersen (meeting) prizes; travel grants; ESPE-Hormone Research in Paediatrics prize; ESPE President's Poster Awards. The majority of ESPE's awards are presented during ESPE's annual meeting. In 2025 the annual meeting took place in Copenhagen, Denmark, and all awards were presented during the meeting.

Website

The Society runs an active website, which publicises worldwide events in endocrinology and related areas, and advertises all of the Society's activities. The website has a patient section, where patient booklets related to common paediatric endocrine conditions can be downloaded in several languages. The website address is www.eurospe.org.

Journal

The Society's official journal is *Hormone Research in Paediatrics*, published monthly by Karger Publishers. The mission of *Hormone Research in Paediatrics* is to improve the care of children with endocrine disorders by promoting basic and clinical knowledge. The journal facilitates the dissemination of information through original papers, mini-reviews, clinical guidelines or novel insights from clinical practice, and abstracts from international congresses in paediatric endocrinology. Periodic editorials from outstanding paediatric endocrinologists also address contemporary research by critically reviewing the major strengths and weaknesses of the studies

Hormone Research in Paediatrics is a hybrid journal, meaning it is a subscription-based (paywall) journal that offers an Open Access option (Karger's Author's Choice model). An electronic subscription to the journal is accessible to all ESPE members via the ESPE website membership area. Abstracts of the studies are available on-line to all and in addition the abstracts from the ESPE Annual Meeting are freely available via the journal website.

Newsletter and news alerts

The Society produces a quarterly digital publication, '*ESPE News*' which is embargoed as a member-only benefit for the first month of publication. This publication ensures that members and non-members are informed about the Society's latest activities as well as wider updates from the field of paediatric endocrinology, and is free to access on-line to all after the embargo period is complete. In addition, ESPE distributes a monthly email newsletter News Alert, including forthcoming dates and deadlines as well as Society news, articles from the media on paediatric endocrinology and information on ESPE vacancies, grants and prizes as well as the Annual Meeting. The News Alert is sent to ESPE members and other subscribers.

Volunteers

The Society's success depends on the time and commitment devoted to it by a body of volunteers, who assist on committees, editorial boards, programme development for meetings, as speakers and chairs, local congress organisation and other activities. The Society is immensely grateful to all these volunteers for their hard work.

A volunteer recruitment drive was organised during the 2023 Annual Meeting resulting in around 40 applications of ESPE members to support various activities and initiatives. The initiative continued to take place in 2024 and 2025 in which different volunteer task forces were established: membership group; snippets; review of ESPE Syllabus; Science Committee Survey.

Financial review

The Society has net outgoing resources for the year of €130,865 (2024: €148,097).

Reserve fund policy

Income to the Society is mainly generated through membership, the annual scientific meeting and industry support for educational and research activities.

The reserve policy takes into consideration the major risks that could face the Society as detailed in the Society's Risk Register and is reviewed by Council four times a year.

The principal risks are assessed in terms of their significance and probability and given a red, amber or green rating according to their potential impact on the Society. These are listed below, along with their impact rating.

1. Cyber security of ESPE website and potential breach of member data. (RED)
2. Significant loss of pharmaceutical sponsorship. (RED)
3. Long-term financial uncertainty beyond ESPE's yearly budgeting period. (AMBER)
4. Lack of awareness by the public of ESPE and paediatric endocrinology. (AMBER)
5. Lack of relationship with advocacy groups. (AMBER)
6. Financial instability due to global events affecting Society's long-term ability to deliver its charitable activities. (AMBER)
7. Relationship with Karger. (AMBER)
8. Securing the relevance and longevity of the Society. (GREEN)
9. Cessation of key suppliers. (GREEN)
10. Loss of leadership. (GREEN)
11. Conflict of interest of Council members and other stakeholders affecting key decisions and lack of trust in governance. (GREEN)
12. Regulatory and legal non-compliance. (RED)
13. Employment issues - compliance and responsibilities. (GREEN)
14. Sanctioned individuals/organisations - membership/events/grants. (GREEN)

The Society's reserve policy was reviewed during 2025, and is designed to allow the Society to continue running its activities for a two-year period, at its current level, after which the projects would be re-evaluated depending on the level of success in generating new revenue streams. Allowing for a two-year period of financial difficulty would also help to minimize the risk of compromising the objectives and core activities of the Society. A reduction in the scale of activities has been assumed, but not large-scale cancellation of projects. It has been assumed that membership income will drop slightly but remain fairly consistent.

Using calculations based on the summary above, Trustees of the Society considered that the required level of readily useable reserves in 2025 should be €2,400,000. As at 31 December 2025, the Society's unrestricted (free) reserves totalled €5,691,690 (2024: €5,795,925), as set out in the Statement of Financial Activities and Note 14 to the financial statements. Restricted funds of €21,776 (2024: €48,406) are held for specific donor-designated purposes and are therefore excluded from readily useable reserves. After setting aside the required €2,400,000, the Society had €3,291,690 at its disposal as at 31 December 2025 to use towards its charitable objectives.

A reserve at this level will provide the security required for ESPE to continue to fulfill its charitable objectives even if its income is reduced. In February 2026 this policy was reviewed by Trustees and confirmed to be €2,900,000 for FYE 2026.

The reserve policy target was reviewed by Trustees in February 2026 and increased to €2,900,000 for FYE 2026, reflecting two years of full operating costs held in reserve should the Society receive no income during that period. This increase reflects the higher level of operating costs anticipated as ESPE builds an in-house staff team and delivers its 2026–2031 Strategy. The Society's unrestricted reserves of €5,691,690 as at 31 December 2025 remain well in excess of this target. The net outgoing resources of €130,865 recorded in the year (2024: €148,097) reflect the initial phase of this planned investment in operating capacity. Trustees have deliberately budgeted for a series of planned deficits over the coming years as reserves are directed towards delivery of the Strategy, including the recruitment and establishment of the in-house staff team, with the expectation that reserves will reduce towards, and be maintained at, the target level of €2,900,000 as this transition is completed. Trustees monitor this position at each quarterly Council meeting via the Strategic and Finance Committee, against the Society's Risk Register and budget forecasts, to ensure reserves remain sufficient to safeguard the Society's charitable objectives throughout this period of change

ACHIEVEMENTS AND PERFORMANCE

Joint Congress between the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) on 10-13 May 2025

This truly joint landmark event, 'Connecting Endocrinology Across the Life Course', brought together paediatric and adult endocrine specialists from across Europe and the rest of the world to meet, collaborate and celebrate endocrinology at The Bella Centre in Copenhagen, Denmark. The event attracted 7,080 paid in-person registrations of which 2,456 were ESPE or ESE members. The event was a huge success for both Societies and a second event is planned for 2029. JointEndo received 3,027 main abstract submissions and 301 late-breaking submissions. Regarding the scientific focus of the abstracts, 33% (992) were paediatric, 55% (1672) were adult, 9% (270) were life course, and 3% (62) were transition. In addition to the scientific sessions, a YES tour and a joint YES-EYES tour took place in Copenhagen.

Schools and courses

Winter School: Poland, February 2025
The ESPE Winter School supported paediatricians who have entirely or partially completed their basic paediatric training and who are now either established in, or intending to develop a deep and continuing interest in paediatric endocrinology and diabetes.
The course extended over five days and was composed of the following:

- Interactive lectures given by experienced ESPE members, with the aim of covering all main topics in paediatric endocrinology
- These lectures will be supplemented by small group sessions discussing teachers' cases; and case presentations by the students
- An introduction into clinical research with presentation by students of research proposals and projects in small groups, and presentation of selected work to the plenum

Priority was be given to applicants with evidence of a commitment to Paediatric Endocrinology through participation in clinical services or attendance at relevant meetings, and to individuals from across Eastern Europe, Africa and the Middle East.

C&CA School: Tbilisi, Georgia, April 2025
This in-person 4-day course was designed for paediatricians from the Caucasus and Central Asia who have completed part or all of their basic paediatric training and are aiming to develop expertise in paediatric endocrinology and diabetes. The 2025 school was dedicated to the memory of Malcolm Donaldson (1949–2024) - a founding figure of the ESPE Caucasus & Central Asia School, a committed teacher, and a visionary leader in paediatric endocrinology. His enduring educational legacy continues to inspire the school and its participants. Malcolm Donaldson had been deeply involved in coordinating and teaching ESPE regional winter schools, including those in Eastern Europe and Central Asia, and was widely recognized for his impact in the field.

There were 25 participants from the following countries: Uzbekistan, Kyrgyzstan, Kazakhstan, Armenia, Azerbaijan, Georgia and Tajikistan.

Program structure and learning content

- Pre-course e-learning:
  Participants received access to the ESPE e-learning platform, with study modules available in both Russian and English. Self-study before the in-person course was strongly encouraged.
- Teaching Format:
  - Keynote lectures delivered by experienced ESPE members and regional experts in paediatric endocrinology. These sessions cover major topics in the field.
  - Small-group sessions where participants and teachers present clinical cases and discuss them collaboratively.
  - Research modules: Introduction to clinical research in paediatric endocrinology, with opportunities for students to present their own project ideas.
  - Student presentations: Each participant presents at least one clinical case, fostering interactive learning.
- Language support:
  The school's main language was English, with presentation slides available in both English and Russian.

Summer School: Denmark, May 2025

The ESPE Summer School took place from the 7-9 May 2025 at the picturesque Konventum, located on the serene coast of Helsingør, Denmark. This beautiful venue, with its stunning sea views and peaceful atmosphere, provided the perfect setting for three days of intensive learning and vibrant discussion. The catering at Konventum was excellent, with delicious meals that catered to the individual needs of both students and faculty.

Despite the shorter interval of only six months between ESPE 2024 and ESPE 2025, an outstanding programme was curated in record time. We are deeply grateful to our hosts, Prof. Katharina Mian and YES representative Dr. Pernille Badsberg Norup, whose meticulous organisation ensured that the entire event ran smoothly.

The Summer School brought together 26 enthusiastic students from 14 different countries, along with 14 expert faculty members who generously shared their expertise and actively engaged in discussions. A highlight of the event was the social evening—a boat ride to see the famous statue of the Little Mermaid. This provided a perfect opportunity for students and faculty to form friendships that will last a lifetime.

The feedback from participants was excellent and also included valuable suggestions for future improvements. One key takeaway was the students' keen interest in more small-group, case-based discussions led by faculty, moving towards a problem-based learning approach rather than solely focusing on student-presented cases.

We look forward to incorporating this constructive feedback into the 2026 programme, ensuring the ESPE Summer School continues to be an inspiring and enriching experience for all.

DOM School: Denmark, May 2025
The DOM School took place from 14–16 May 2025 at Konventum, Helsingør, Denmark. The school was locally hosted by Jesper Johannesen (Rigshospitalet, Copenhagen), whose support contributed to another successful DOM School.

The DOM School brought together a cohort of senior trainees from multiple countries. This DOM School edition counted 11 expert facilitators and faculty who shared their expertise in some selected areas of diabetes, obesity and metabolism and promoted discussions and interactions between young physicians and senior paediatric endocrinologists and to develop future leaders in Paediatric Endocrinology.

Moldova Course
The teaching school was held in a rural location close to Chisinau, the capital of Moldova from 5-8 June 2025. The school provided networking and continuous medical education in paediatric endocrinology and diabetes for English-speaking fellows from Moldova, Ukraine, and Romania.

Maghreb School
The 2025 ESPE Maghreb School was held in Tunis, the capital of Tunisia over 4 days in late November 2025.
The meeting, which was conducted as usual in the French language, marked the third of the three-year cycle of this teaching programme and hence the 13th Maghreb School to date.

This year's teaching faculty comprised eight professors from the Maghreb Countries: Asmahane Ladjouze [coordinator], Yasmine Ouarezki and Sakina Kherra from Algeria; Zineb Imane and Sana Abourazzak from Morocco; and Saayda Ben Becher, Thouraya Kamoun (local coordinator) and Sana Kmiha (local coordinator) from Tunisia; and four colleagues from Europe and Canada: Régis Coutant from France, Lorenzo Iughetti from Italy, and Rasa Verkauskiene from Lithuania. We were sad to say goodbye Cécile Brachet from Belgium and were very sad for the loss of Pr Sayda Ben Becher from Tunisia), but glad to welcome Raiy El Quadiry from Morocco, and Melanie Henderson and Cheri Deal from Canada.

The student faculty consisted of 29 students from Algeria, Morocco, Tunisia and one student from Mauritania.

We started and ended our school by a tribute to Juliane Léger who was the founder of the Maghreb school and Pr Saayda Ben Becher one of the faculty founders of the Maghreb school, as they both passed away this year.

ASPED-ESPE Endocrine Academy, December 2025
ASPED-ESPE Endocrine Academy is aimed at fellows, trainees and junior consultants in Paediatric Endocrinology practicing in Arab countries. The School is designed for fellows, trainees and junior consultants in Paediatric Endocrinology practicing in Arab countries.The 2025 Academy took place 6-8 December 2025 in Jeddah, with 30 students from ASPED and ESPE. The first ASPED ESPE Rare Disease Summit was held back-to-back with the Academy in Jeddah and was open to other local students because of funding from local companies.

European Training Requirements

The aim of the European Training Requirements (ETR) in Paediatric Endocrinology & Diabetes (PED) is to provide harmonisation of education and training in paediatric endocrinology using the highest standards among European countries, in collaboration with other paediatric subspecialties participating in European Academy of Paediatrics.

The ETR in PED includes standards for training, trainers and training institutions. It includes a syllabus, trainee assessment methodology, and trainer and training centre requirements.

The ETR provides detailed specialty specific content that trainees are expected to achieve in order to become competent independent clinicians. A downloadable syllabus tracker and self-assessment tool enables trainees to self-assess and monitor their progress over the course of their training.

The latest ETR in PED was approved by the European Academy of Paediatrics (EAP), European Board of Paediatrics (EBP) and Union of European Medical Specialists (UEMS) in 2021. During 2025 and 2026 the ESPE 'ETR Taskforce' of volunteers led by Leena Patel worked on updating the ETR in PED. In March 2026 the draft ETR was submitted to the EAP and EBP for their review and approval. It was included on the agenda of the Secondary–Tertiary Care Council session during the EAP Spring Meeting in Tallinn, Estonia in May 2026.

Following approval by the EAP / EBP, the 2026 ETR has been submitted to the UEMS for adoption. The UEMS Autumn Council meeting will take place in October 2026 in Brussels.

EUPET

The EUPET taskforce and volunteers led by Michael Hauschild, aims to develop and maintain a harmonised European training programme in PED, fully aligned with the standards required by UEMS European Training Requirements and included in the ESPE ETR. Its mission is to translate these standards into a structured, competency-based ESPE training programme, focused on clinical situations, learning objectives, and achievement of learning. Through close collaboration with ESPE education bodies, EUPET seeks to support high-quality, consistent specialist training across Europe.

Academies

Bone Academy

The Bone Academy is a new ESPE activity and is designed for mid-career physicians with a strong interest in paediatric bone disease, including clinicians established in their practice who seek to deepen their expertise in diagnosing, treating, and managing rare and complex bone conditions in children and adolescents. The program will enhance clinical skills, provide the latest scientific insights, and offer practical strategies to improve patient outcomes.

By addressing the unique challenges of paediatric bone diseases, the Academy will help participants stay at the forefront of advancements in the field, empowering them to lead in clinical practice, research, and multidisciplinary collaboration. Attendees will also have the chance to engage with experts and peers, expanding their professional network and fostering ongoing learning in paediatric endocrinology.

Programme

The ESPE Bone Academy is a two-year, structured program that combines in-person and online sessions, offering a balanced approach to education. Designed for mid-career and senior physicians, this academy will guide you through the latest advancements and provide practical tools to confidently diagnose, treat, and manage paediatric bone diseases.

The Bone Academy is planned a specialised, long-term education program designed to meet the growing needs in paediatric bone health, designed for mid-career and senior physicians. The ESPE Bone Academy will be split into 14 modules, starting with a 1.5 day in-person meeting in Paris, France, in February 2026.

The Leadership Academy
A new educational academy focused on training in teaching, leadership, and management skills to prepare paediatric endocrinologists to become future leaders for ESPE educational and academic activities was approved by ESPE Council during 2025.

- The first 2-day face-to-face course will take place in November 2026 in Cairo, Egypt
- A total of 25 ESPE School alumni will be selected based on their participation during 2024 and 2025.
- The curriculum will encompass a hot scientific topic in addition to dedicated sessions to develop specific skills such as teaching, presentation, dealing with pharma companies, manuscript writing and reviewing, journal editing, grant applications and fund raising.
- The curriculum will be delivered through plenary lectures and small group interactive sessions.
- The faculty will consist of senior ESPE members with experience in the above areas.

Spotlight on Education in Developing Countries
ESPE continued to support education of paediatric endocrinology in developing countries, through:

- supporting the PETCA project
- delivering the ESPE Winter, Summer and DOM School in person to enable access to high quality teaching
- delivering Caucasus & Central Asia School in person
- running the ESPE Clinical Fellowship for fellows from developing countries to gain access to high quality educational experience in top European centres for 3-6 months
- provision of multilingual facilities on the e-Learning portal
- provision of patient information leaflets for common paediatric endocrine disorders in multiple languages

ESPE Connect webinars
ESPE Connect webinars offer high-quality scientific and educational content from world-leading paediatric endocrinologists. ESPE Connect presents the latest developments covering all areas of paediatric endocrinology that you can view whilst it's broadcast live or on-demand at your convenience. The webinars are free to attend, but on-demand replays are only available to ESPE Members in the member area.

- Neonatal thyroid 20th ESPE Connect Webinar - Wednesday 10 December 2025
- Prader-Willi Syndrome 19th ESPE Connect Webinar – 2 October 2025
- Diagnostics 18th ESPE Connect Webinar - 8 July 2025
- Management of monogenic, neonatal and rare forms of diabetes mellitus 17th ESPE Connect Webinar - 29 January 2025

Grants and Fellowships
In 2025, ESPE's expenditure on grants, fellowship and awards to members and beneficiaries totalled €428,665 (2024: €303,564), as set out in Note 6 to the financial statements – a return to pre-pandemic levels of funding.

Travel grants
The ESPE Travel Grant is intended to support the participation of junior delegates such as fellows in training, post–docs and PhD students for attendance of the ESPE Annual Meeting if the applicant has submitted a high-quality abstract. In 2025 ESPE provided 39 Travel Grants for participants at the Joint Congress in May 2025.

Scientific grants
The Science Committee, which oversees ESPE's suite of grants, carried out its activities as normal in 2025 and was able to manage the process of and award all its grants as normal.

In 2025, ESPE awarded the following grants:

Clinical Fellowship Grant
The Clinical Fellowship aims to promote the development of patient care, clinical management, and clinical research in paediatric endocrinology through a training programme in a European Clinical centre

In 2025, there were 23 awardees, namely Alapan Mahapatra (India), Bushra Naseer Khan (Pakistan), Dr Sibi Kaivallyam Ramachandran (India), Dr. Vrushali Takalikar (India), Eleni Ramouzi (Greece), Hanife Gul Balki (Turkey), Heera Nand Rathore (Pakistan), Hiwot Nida Semoro (Ethiopia), Jahnavi M (India), Jyotsna Venkatamathi Padmanabhan (India), Karishma Bhade (India), Marguerite Edongue Hika (Cameroon), Mariam Mohamed Ismail Mohamed (Sudan), Olha Shevchenko (Ukraine), Vibha Yadav (India), Duygu Özbek Siddiqui (Turkey), Irina Muradyan (Armenia), Manduukhai Batsukh (Mongolia), Phoebe Wamalwa (Kenya), Akshatha A (India), Anu Tresa Esaiselvan (India), Aygun Musayeva (Azerbaijan), Meghana Narasimhegowda (India).

Research Fellowship Grant
The Research Fellowship enables talented early-career scientists, investigators, and paediatric endocrinologists to conduct research at leading institutions worldwide. This outstanding programme has helped launch powerful careers in leading-edge clinical research in paediatric endocrinology. In 2025, the awardee was Diana Pierlugi, Milan, Italy. The award was not payable until 2026.

Early Career Scientific Development Grant
The Early Career Scientific Development Grant is supported by ESPE, and it offers financial support to paediatric endocrinologists and basic scientists for the purpose of gathering information and experience on a specific research issue or on a laboratory technique in the field of paediatric endocrinology. The awardees in 2025 were Anna Fedorczak (Poland), Angela Lucas-Herald (UK) and Simge Eren (Turkey).

Research Unit Grant
The ESPE Research Unit Grant is a collaborative research grant which aims to foster, facilitate, coordinate, and identify topics for high quality research in paediatric endocrinology, for both physicians and scientists. In 2025, the awardees were Jan Idkowiak (UK), Christa Flueck (Switzerland), Chrysanthi Kouri (Switzerland), Elizabeth Baranowski (UK), Wiebke Arlt (UK), Rodolfo Rey (Argentina) for a project entitled Long-term health outcomes in Congenital Adrenal Hyperplasia due to Cytochrome P450 oxidoreductase deficiency (PORD). No payments in respect of the grant were made during 2025.

Visiting Professorship
The ESPE Visiting Professorship of Rare Diseases Grant enables scientific renewal and the development and sustaining of long-term partnerships that lead to the development of new projects and funding, for established paediatric endocrinologists. In 2025 the awardee was Prof. Ken McElreavey (France).

Awards

ESPE is proud to present prestigious awards recognising winners' achievements at different stages of their careers, across the field of paediatric endocrinology.

Andrea Prader prize
The Andrea Prader Prize is an annual Leadership Award given to an ESPE member. It is the most prestigious ESPE award, given in recognition of excellence in leadership, a lifetime achievement in teaching and research, and an outstanding overall contribution to the field of paediatric endocrinology. In 2025 the awardee was Olle Söder, Solna, Sweden.

Research award
The Research Award recognises research achievements of outstanding quality in the fields of basic endocrine science or of clinical paediatric endocrinology. In 2025 the awardee was John Achermann, London, UK.

International research award
The International Research Award recognises research achievements of outstanding quality in the fields of basic endocrine science or of clinical paediatric endocrinology. Candidates must be from a country outside Europe and the Mediterranean basin. In 2025 the awardee was Thomas Carpenter, New Haven, USA.

International outstanding clinician award
The International Outstanding Clinician Award recognises an outstanding contribution and lifetime commitment to the practice of clinical paediatric endocrinology in a country outside Europe and the Mediterranean basin. The award aims to strengthen the relationship between ESPE and its sister societies and to acknowledge excellence in paediatric endocrinology around the world. In 2025 the awardee was Paul Hofman, Auckland, New Zealand.

Outstanding clinician award
The Outstanding Clinician Award was established in 2001 and recognises outstanding clinical contribution to the practice of Clinical Paediatric Endocrinology. In 2025 the awardee was Marco Cappa, Rome, Italy.

Young investigator award
The Young Investigator Award recognises outstanding scientific work by practising paediatricians who are ESPE members. The evaluation is based on the overall quality of a candidate's CV in this regard and, in particular, on three original publications submitted by each applicant. In 2025 the awardee was Rebecca Moon, Southampton, UK.

Hormone Research award
The annual ESPE Hormone Research in Paediatrics Award, initiated in 2004, rewards a young clinical or experimental scientist for the best original paper and novel insights from clinical practice published in Hormone Research in Paediatrics. In 2025 the awardees were Dr. Antonia Dastamani (UK) and Dr. And Demir (Finland). The ESPE Hormone Research in Paediatrics Award is not paid by ESPE but is paid directly by Karger.

Henning Andersen prize
The Henning Andersen Prizes are two awards for the most highly rated clinical and experimental abstracts submitted to the Society's Annual Meeting. In 2025 the awardees were Jinting Zhou, Xi'an, China and Luis Gustavo Perez-Rivas, Munich, Germany. No payments in respect of the prizes were made during 2025.

ESPE undergraduate achievement award
The ESPE Undergraduate Achievement Award aims to attract early-career scientists and clinicians into paediatric endocrinology at the undergraduate level by recognising high achievement in the field. Given the increasing emphasis on specialisation at an earlier stage in career development, there is a need to increase exposure to paediatric endocrinology during the early formative years. In 2025 the awardees were Lena Van de Wynkele, Ghent, Belgium and Henri Couckuyt, Ghent, Belgium.

President poster award
The ESPE President Poster Award is bestowed to the presenting and first author of five selected poster presentations at the Annual Meeting. In 2025 the awardees were Mohamed Abubaker (UK), Merisa Abusdal (Norway), Corin Badiu (Romania), Felix Chelslin (Sweden), Nathalie Erpelding (USA), Isabel Viola Frielitz-Wagner (Germany), Laura Lucaccioni (Italy), Malene Asp Bock Mejdahl (Denmark), Sema Okutan (Denmark), Luigi Picaro (UK), Philippa Prentice (UK), Mercedes Rivera Cuello (Spain), Patrice Rodien (France), Carin Skogastierna (Sweden), Lorenzo Tucci (Italy) and Yi Wang (China).

Website
The ESPE website is the Society's largest marketing channel and a key platform for informing paediatric endocrinologists about ESPE activities. This is supplemented by a range of other communication tools as detailed below, which drive traffic back to the central ESPE website.

Communications
ESPE continues to communicate to its members through multiple channels, including the quarterly digital publication *ESPE News*, a monthly email newsletter News Alert, dedicated email messaging, the website, and social media, (Facebook, X, Instagram, and LinkedIn).

In 2025, ESPE increased the number of followers across all platforms to 13,324 – an increase of 17.8% on 2024. ESPE also received a total of 318,749 impressions (the total number of views on a piece of content) – an increase of 11.1% on 2024. ESPE increased the number of website users to 127,059 (an increase of 11.5% on 2024).

Journal

The official ESPE journal continues to be *Hormone Research in Paediatrics*. Karger continues to publish the journal and supports two *Hormone Research in Paediatrics* prizes. These are awarded at the annual conference.

Membership

During the year our membership numbers increased, with 501 new membership applications approved by Council. Membership totalled 1,405 in comparison to 1,243 in 2024. Although this presents a steady increase in membership, membership recruitment and retention was a key focus towards the end of the year.

European and International collaboration

ESPE continues to be part of the International Consortium of Paediatric Endocrinology (ICPE) and is represented at its meetings by the President and Treasurer. This virtual network involves reference centres across Europe and aims to tackle complex or rare endocrine conditions that require highly specialised treatment and a concentration of knowledge and resources. In 2031 ESPE will host the ICPE meeting in Europe.

ESPE has active collaborations with many if its sister societies around the world, including the European Society for Endocrinology (ESE) with whom it organised the Joint Congress in 2025, the EndoCompass project and the Transition guidance in 2026. Further details are included in the following sections.

Clinical Practice Committee

During 2025 the following ESPE publications were either published or in press:

- European Society for Paediatric Endocrinology and European Society of Endocrinology Joint Clinical Practice Guidance for Healthcare Transition from Paediatric to Adult Endocrine Care
- International guideline on genetic testing of children with short stature
- Unmet Medical Needs in Pediatric Endocrinology: A Position Statement from the European Society for Paediatric Endocrinology Clinical Practice Committee and Council Joint Initiative
- Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibitors: A Position Statement from the Clinical Practice Committee of the European Society for Pediatric Endocrinology
- The EndoCompass Research Roadmap – Directions for the Future of Endocrine Science

Policy and advocacy activities

Endocompass

The EndoCompass project, led by ESE and ESPE, during 2024 and 2025 sets out strategic recommendations to strengthen endocrine science and improve hormone health in Europe. Developed by 228 experts from across Europe, it identifies where targeted research and investment can deliver the greatest impact to inform policy and funding decisions, while guiding researchers and clinicians in their work. The Roadmap was published in October 2025 as a supplement to the *European Journal of Endocrinology* and shortly thereafter in *Hormone Research in Paediatrics*.

Toy regulations

ESPE was heavily involved in the lead-up to the 10 April 2025 political agreement on the new EU Toy Safety Regulation, acting as a scientific advocate for stricter chemical restrictions to protect child health. ESPE worked alongside other organisations, including the Endocrine Society and the European Society of Endocrinology, to call for the restriction of these substances in toys, which are a key source of child exposure.

Chemicals Omnibus and Chemicals Action Plan

In July 2025 ESPE, together with ESE and the Endocrine Society, released a joint statement expressing deep concern over the European Commission's proposed Chemicals Omnibus Package and Chemicals Action Plan. While these initiatives are presented as efforts to streamline legislation and enhance industrial competitiveness, ESPE warned that they risk significantly weakening consumer protections and endangering public health, particularly for vulnerable populations such as children and pregnant women.

Many endocrine-disrupting chemicals (EDCs) and carcinogenic, mutagenic, and reprotoxic (CMR) substances are found in everyday products, including cosmetics, and are linked to serious health conditions such as cancer, infertility, obesity, and neurodevelopmental disorders.

The societies supported a universal restriction on per- and polyfluoroalkyl substances (PFAS), with exceptions only for essential uses where no alternatives exist. ESPE advocated for regulatory measures that consider the persistence of these substances and call for an immediate ban in consumer products such as cosmetics, food contact materials, and outdoor clothing.

ESPE reaffirmed its commitment to working with EU institutions to ensure that chemical regulations prioritise human health. It pledges to bring the hazards of EDCs for children's health and well-being to the attention of policymakers to raise awareness and set in place a regulatory framework that effectively protects children from harmful exposure.

EU Pharmaceutical Package and policy reforms

ESPE has also been actively involved in the EU Pharmaceutical Package and broader EU policy reforms by advocating for stronger regulation of Endocrine Disrupting Chemicals (EDCs) and improved paediatric medicine access and market authorisation process of paediatric drugs. They have partnered with other endocrine societies to urge EU policymakers to prioritize child health by limiting exposure to EDCs in consumer products.

The overall EU Pharmaceutical Package, which was partially in negotiations as of early 2026, aims to improve paediatric medicines (PMPs) by accelerating approval times and improving access, with input from clinical experts like the ESPE on the needs of children with endocrine disorders

Funding for paediatric health research

FP10 (2028–2034) is the upcoming European Union Research and Innovation Framework Programme, proposed with a potential budget of between €175 billion and €220 billion, focusing on collaborative, cross-border research. It will prioritize green/digital transitions, health, security, and competitiveness, featuring enhanced European Research Council (ERC) and European Innovation Council (EIC) support. ESPE is seeking reach out to the EU institutions on the importance of paediatric health research and funding opportunities for paediatric endocrine research in the FP10 programme. This requires continued input to the work of the Biomed Alliance Health Research Committee and continued monitoring of funding opportunities.

Administration and organisational structure

In 2025, ESPE recruited Dr Kay Miller as its CEO and first member of permanent staff. Kay's role is to oversee the day-to-day operations of the Society and to provide governance and strategic support to ESPE Council. As CEO Kay works in close collaboration with ESPE Council to develop and deliver ESPE's future strategy. MCI (ESPE's contracted association management company) continue to be engaged as association managers, to provide the secretariat and association management services, and Interplan provide professional congress organisation services for the Annual Meeting. The role of Senior Operating Officer is provided by MCI Brussels, to co-ordinate all activities and provide additional strategic support to ESPE Council.

PLANS FOR FUTURE PERIODS

In 2026, ESPE will continue its established activities as described in this report and develop its new strategy for the period 2026-2030.

As part of our strategy we will maintain our focus on:

- A review of our membership categories, fees and benefits
- Our International Education and Training Programme, including our Schools and Academies
- The delivery of online content via a new eLearning platform, new academies and the ESPE Connect and YES Group webinar series. In addition, content from the annual scientific meeting which will take place in Marseille in 2026 will also be delivered online.
- The continued development of our excellent Annual Meeting series
- Our commitment to support science and research in the field with our own grants and fellowships programme, and we will reach out to the EU institutions on the importance of paediatric health research and funding opportunities for paediatric endocrine research in the FP10 programme.
- Supporting the paediatric endocrinology community, including out patients and Patient Advocacy Groups and our Affiliated Societies.

RESPONSIBILITIES OF THE TRUSTEES

The trustees are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are also responsible for the maintenance and integrity of the information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charity's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

AUDITOR

A resolution to formally appoint Crowe U.K. LLP as auditor for the ensuing year was approved by members at the 2025 Annual General Meeting.

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Registered office:
RWK Goodman
69 Carter Lane
London
EC4V 5EQ

Signed on behalf of the trustees
on 7 September 2026



Professor Rasa Verkauskiene
Treasurer, ESPE

`

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY

Opinion

We have audited the financial statements of European Society for Paediatric Endocrinology ('the charitable company') for the year ended 31 December 2025 which comprise the Statement of Financial Activities, Balance Sheet and Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY

Opinions on other matters prescribed by the Companies Act 2006
In our opinion based on the work undertaken in the course of our audit

- the information given in the trustees' report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In light of the knowledge and understanding of the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the trustees' directors' report and from the requirement to prepare a strategic report.

Responsibilities of trustees
As explained more fully in the trustees' responsibilities statement set out on pages 16 to 19, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team members. We then designed and

performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.

We obtained an understanding of the legal and regulatory frameworks within which the charitable company operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 together with the Charities SORP (FRS102) 2019. We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company for fraud. The laws and regulations we considered in this context for the UK operations were Charity Commission Regulations. Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any.

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the recognition of grant/contract income and the override of controls by management. Our audit procedures to respond to these risks included vouching a sample of signed income agreements in the year financial records and to bank statements, enquiries of management and the Trustees about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing accounting estimates for biases, and reading regulatory correspondence with the Charity Commission and minutes of governance meetings.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Alan Reynolds
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
3rd Floor, St George's House
56 Peter Street
Manchester
M2 3NQ

Date: 23 September 2026

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 31 DECEMBER 2025

	Notes	Restricted Funds 2025	Unrestricted Funds 2025	Total Funds 2025	Total Funds 2024
		€	€	€	€
INCOME AND ENDOWMENTS FROM:					
Charitable activities	3	**227,000**	**52,273**	**279,273**	3,531,430
Investments	4	**-**	**28,902**	**28,902**	30,521
Other trading activities	5	**-**	**1,290,848**	**1,290,848**	140,357
TOTAL INCOMING RESOURCES		**227,000**	**1,372,023**	**1,599,023**	3,702,308
EXPENDITURE ON:					
Charitable activities	6	**(482,295)**	**(1,247,593)**	**(1,729,888)**	(3,850,405)
TOTAL RESOURCES EXPENDED		**(482,295)**	**(1,247,593)**	**(1,729,888)**	(3,850,405)
NET INCOME/(EXPENDITURE) FOR THE YEAR BEFORE TRANSFERS	9	**(255,295)**	**124,430**	**(130,865)**	(148,097)
Transfers between funds	14	**228,665**	**(228,665)**	**-**	-
NET MOVEMENT IN FUNDS		**(26,630)**	**(104,235)**	**(130,865)**	(148,097)
RECONCILIATION OF FUNDS:					
Total funds brought forward		**48,406**	**5,795,925**	**5,844,331**	5,992,428
TOTAL FUNDS CARRIED FORWARD		**21,776**	**5,691,690**	**5,713,466**	5,844,331

The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities.

The notes on pages 27 to 36 form part of these financial statements.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

BALANCE SHEET

YEAR ENDED 31 DECEMBER 2025

		2025		2024	
	NOTE	€	€	€	€
FIXED ASSETS					
Investment in Joint venture	**11**		**60**		60
CURRENT ASSETS					
Debtors	**12**	**1,568,929**		911,242	
Cash at bank		**5,001,117**		5,743,685	
		6,570,046		6,654,927	
CREDITORS: Amounts falling due within one year	**13**	**(856,640)**		(810,656)	
NET CURRENT ASSETS			**5,713,406**		5,844,271
TOTAL ASSETS LESS CURRENT LIABILITIES			**5,713,466**		5,844,331
NET ASSETS			**5,713,466**		5,844,331
FUNDS					
Unrestricted income funds	**14**		**5,691,690**		5,795,925
Restricted funds	**14**		**21,776**		48,406
TOTAL FUNDS			**5,713,466**		5,844,331

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

These financial statements were approved and authorised for issue by the members of the committee on 7 September 2026 and are signed on their behalf by:



Professor Rasa Verkauskiene
Treasurer, ESPE

Company Registration Number: 05766541

The notes on pages 27 to 36 form part of these financial statements.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

STATEMENT OF CASH FLOWS

YEAR ENDED 31 DECEMBER 2025

		2025	2024
		€	€
Cash flows from operating activities	**17**	**(742,568)**	409,626
Cash flows from investing activities	**18**	**-**	(60)
Change in cash in the year		**(742,568)**	409,566
Cash at the beginning of the year		**5,743,685**	5,334,119
Cash at the end of the year		**5,001,117**	5,743,685

Analysis of net debt

	At 1 January 2025	Cashflow	At 31 December 2025
	€	€	€
Cash in hand, at bank	5,743,685	(742,568)	5,001,117
	5,743,685	**(742,568)**	**5,001,117**

The notes on pages 27 to 36 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 DECEMBER 2025

1. ACCOUNTING POLICIES

Charitable company information
The European Society of Paediatric Endocrinology (ESPE) is a private limited charitable company, limited by guarantee by not having any share capital, incorporated and domiciled in England and Wales. The registered office is RWK Goodman, 69 Carter Lane, London, EC4V 5EQ.

Basis of accounting
The financial statements have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Charities Act 2011 and the Companies Act 2006.

Joint venture: ESPE holds a 50% interest in JointEndo Limited, a jointly controlled entity. The investment is being accounted for at cost, in line with a policy choice available within FRS 102 and is included in the financial statements at €60, being the initial share subscription. The joint venture is not consolidated in these financial statements. During the year, JointEndo Limited generated a surplus and in accordance with the shareholder agreement, has declared a Gift Aid distribution. ESPE's share of €1.20m has been recognised in the Statement of Financial Activities as income from other trading activities.

The company constitutes a public benefit entity as defined by FRS 102.

Going concern
The Trustees have undertaken detailed planning and forecasting work, in order to ensure that the charity's financial resources and contingency planning are sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least twelve months from the date of approval of these financial statements. The Trustees have therefore prepared the financial statements on a going concern basis. With the help of the strategic and finance committee, the Trustees have undertaken detailed planning for future annual meetings beyond the next 12 months, including the 2026 annual meeting to be held in Marseille.

In addition to the annual meeting, the society continues to maintain contact with its members through different activities including the award of fellowships and grants, the organisation of specialist events, and online teaching activities.

The preparation of the financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Charitable Company's accounting policies (see note 2).

Incoming resources
Sponsorships, membership subscriptions and investment income are accounted for on an accruals basis. Gift aid from Joint venture income is recognised on an accruals basis when the charitable company has entitlement, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

Resources expended
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Support costs are allocated to expenses where they are incurred in direct relation to the expense, elsewhere they are allocated on a percentage of overall expenses incurred.

1. ACCOUNTING POLICIES (CONTINUED)

Governance costs include those costs incurred in the governance of the charity. These costs include costs related to statutory audit together with legal and professional fees and the costs of trustee meetings.

Foreign currencies
The company's functional and presentational currency is Euros. The exchange rate between sterling and the Euro at 31 December 2025 was £1: €1.15.

Assets and liabilities in foreign currencies are translated into Euros at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into Euros at the rate of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the net incoming resources for the year.

Financial instruments
The company only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

Investments in joint ventures
ESPE holds a 50% interest in JointEndo Limited ("JEL"), a company incorporated in the UK, which is a jointly controlled entity as defined by FRS 102. The investment is carried at cost, being the initial share subscription of €60, in accordance with the cost basis policy available under FRS 102 Section 15. JointEndo Limited is not consolidated in these financial statements.

Fund accounting
General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

2. Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows;

Irrecoverable debt provision
The company makes an estimate of the recoverable value of VAT from overseas countries. When assessing the impairment of VAT recoverable, management considers factors including the ageing profile of VAT recoverable and past experience of the recovery from authorities involved. On this basis, a provision was made against the balance recoverable. This provision is included within irrecoverable debt expense.

3. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES

	Restricted Funds 2025	Unrestricted Funds 2025	Total Funds 2025
	€	€	€
Annual congress income	-	-	-
Fellowships	**200,000**	-	**200,000**
Schools	**23,000**	-	**23,000**
Awards	**4,000**	-	**4,000**
Other activities	-	**52,273**	**52,273**
	227,000	**52,273**	**279,273**

	Restricted Funds 2024	Unrestricted Funds 2024	Total Funds 2024
	€	€	€
Annual congress income	-	3,329,418	3,329,418
Fellowships	155,000	-	155,000
Schools	512	-	512
Awards	4,000	-	4,000
Other activities	-	42,500	42,500
	159,512	3,371,918	3,531,430

Impact of Joint venture

Readers reviewing these financial statements alongside those of the prior year will note a significant reduction in both total income and total expenditure. This does not reflect a reduction in the scale or scope of ESPE's activities but is instead a consequence of a change in the structure through which the annual congress was delivered in 2025, as explained below.

In prior years, ESPE organised and delivered its annual congress directly. In accordance with the SORP, all gross income generated by the congress and all related expenditure were recognised in full within Charitable Income and Charitable Expenditure respectively in ESPE's Statement of Financial Activities ("SoFA").

With effect from November 2024, ESPE entered into a joint venture with the European Society of Endocrinology (ESE) to co-deliver an annual congress in 2025 through JEL As a result of this change in structure, the gross income and expenditure of the congress is no longer recognised. Under FRS 102, ESPE's investment in JEL is carried at cost and only distributions received from JEL are recognised as income by ESPE.

During the year, JEL organised and delivered the joint annual congress held in Copenhagen, which was highly successful. JEL generated a surplus from the congress and, in accordance with the shareholder agreement, declared a Gift Aid distribution. ESPE's share of €1.2 m has been recognised as income from other trading activities in the SoFA.

The practical effect is that, compared to the prior year, both income and expenditure as reported in ESPE's accounts are approximately €1.7m lower than they would have been had the congress continued to be delivered directly. This presentation is consistent with the requirements of FRS 102 and the Charities SORP and accurately reflects ESPE's legal and financial relationship with JEL. The ESPE trustees are satisfied that the underlying charitable activity and financial performance of the organisation remain strong.

4. INVESTMENT INCOME

	Restricted Funds	Unrestricted Funds	Total Funds 2025
	€	€	€
Bank interest receivable	-	28,902	28,902

	Restricted Funds	Unrestricted Funds	Total Funds 2024
	€	€	€
Bank interest receivable	-	30,521	30,521

5. OTHER TRADING ACTIVITIES

	Restricted Funds	Unrestricted Funds	Total Funds 2025
	€	€	€
Membership subscriptions	-	86,780	86,780
Gift Aid from Joint Venture	-	1,204,068	1,204,068
	-	1,290,848	1,290,848

	Restricted Funds	Unrestricted Funds	Total Funds 2024
	€	€	€
Membership subscriptions	-	140,357	140,357

See note 3 for details on the Gift Aid from Joint Venture.

6. COSTS OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE

	Direct charitable activities	Support costs (note 7)	Total Funds 2025
	€	€	€
Grants	428,665	122,063	550,728
Education & training	430,338	193,934	624,272
Membership	-	24,339	24,339
Annual meetings & events	-	97,335	97,335
Annual congress expenditure	97,172	5,848	103,020
Newsletter & website	22,463	1,333	23,796
Society management fee	-	306,398	306,398
	978,638	751,250	1,729,888

Direct grants are made up of the following:

	2025	2024
	€	€
Research Unit	**50,000**	40,000
Visiting professorship	**5,000**	15,000
Clinical Fellowship	**108,672**	101,064
Research Fellowship	**264,993**	140,000
Early Career Award	**-**	7,500
	428,665	303,564

	Direct charitable activities	Support costs (note 7)	Total Funds 2024
	€	€	€
Grants	303,564	19,577	323,141
Education & training	307,420	144,361	451,781
Membership	-	37,733	37,733
Annual meetings & events	-	88,994	88,994
Annual congress expenditure	2,218,458	-	2,218,458
Newsletter & website	11,833	-	11,833
Society management fee	-	208,726	208,726
Irrecoverable debt expense	-	509,739	509,739
	2,841,275	1,009,130	3,850,405

See note 3 for details on the reduction to annual congress expenditure.

7. SUPPORT COSTS

		2025	2024
		€	€
Office expenses		**25,075**	37,733
Reimbursement of salary costs		**27,500**	52,708
Professional consultancy fees		**491,461**	287,013
Foreign exchange losses		**21,011**	13,366
Miscellaneous		**14,449**	1,331
Irrecoverable debt expense		**-**	509,739
Governance costs	Note 8	**171,754**	107,240
		751,250	1,009,130

8. GOVERNANCE COSTS

	Unrestricted Funds	Total Funds 2025	Total Funds 2024
	€	€	€
Bank charges	**10,522**	**10,522**	8,909
Auditors' remuneration	**46,499**	**46,499**	39,337
Council and committee meetings	**97,335**	**97,335**	58,994
Professional consultancy fees	**17,398**	**17,398**	-
	171,754	**171,754**	107,240

9. NET INCOME/(EXPENDITURE) FOR THE YEAR

This is stated after charging:

	2025	2024
	€	€
Auditor's remuneration	**46,499**	39,337

During both financial years presented in these financial statements, the charity has benefitted from the contribution of unpaid volunteers, but on the basis that this contribution cannot be accurately valued, no financial impact has been recognised.

No voluntary income that has been recognised in the accounts due to unfulfilled conditions or other contingencies attaching to them.

10. STAFF COSTS AND TRANSACTIONS WITH TRUSTEES

During the year, the charitable company paid €5,988 (2024: €14,539) to 8 trustees (2024: 8) for reimbursement of travel expenses.

Total remuneration and benefits payable to key management personnel during the year were €52,720 (2024: €nil). A total of €7,734 was owing at the year end and is included in other creditors due within one year.

Reimbursement of €27,500 of salaries (2024: €52,708) have been paid for work carried out on behalf of the charitable company during the year.

Fees relating to ESPE Society management are included in Reimbursement of salary costs and Professional consultancy fees as part of support costs – see note 7.

The average number of employees for the year was Nil (2024 – Nil).

11. INVESTMENTS IN JOINT VENTURES

European Society for Paediatric Endocrinology ('the charitable company') owns 50% of the 100 £1 ordinary shares in Jointendo Limited (Registration number 15531364) incorporated in the United Kingdom. The company has total assets less current liabilities at 31 December 2025 of €121 (2024: (€24,616)) and it's trading profit for the year before gift aid was €2,408,136 (2024 – (€24,737)).

12. DEBTORS

	2025	2024
	€	€
Trade debtors	**59,402**	215,094
Prepayments and accrued income	**220,390**	273,473
Amounts due from joint ventures	**1,204,068**	208,558
VAT debtor	**85,069**	175,430
Other debtors	**-**	38,687
	1,568,929	911,242

13. CREDITORS: Amounts falling due within one year

	2025	2024
	€	€
Accruals and deferred income	**492,725**	494,119
Other creditors	**309,915**	316,537
Grants payable	**54,000**	-
	856,640	810,656

The movement on deferred income is as follows:

	2025
	€
Deferred income brought forward	**-**
Amounts released in the year	**-**
Amounts deferred in the year	**471,298**
Deferred income carried forward	**471,298**

14. STATEMENT OF FUNDS

	Balance at 1 January 2025	Incoming resources	Outgoing resources	Transfers	Balance at 31 December 2025
	€	€	€	€	€
General Unrestricted Funds	**5,795,925**	**1,372,023**	**(1,247,593)**	**(228,665)**	**5,691,690**
Restricted Funds					
Fellowships	**-**	**200,000**	**(373,665)**	**173,665**	**-**
Scholarships	**-**	**-**	**(55,000)**	**55,000**	**-**
Schools	**-**	**3,000**	**(382)**	**-**	**2,618**
Awards	**1,885**	**4,000**	**(4,000)**	**-**	**1,885**
Other activities	**46,521**	**20,000**	**(49,248)**	**-**	**17,273**
	48,406	**227,000**	**(482,295)**	**228,665**	**21,776**
TOTAL FUNDS	**5,844,331**	**1,599,023**	**(1,729,888)**	**-**	**5,713,466**

14. STATEMENT OF FUNDS (continued)

Fellowships and Scholarships

Grants allocated to young and senior members for travel and expenditure on short term or long term clinical or scientific research projects.

Schools

Funds allocated for the organisation and housing of faculty and participants for various teaching courses.

Awards

Funds allocated to reward somebody with a prestigious career in paediatric endocrinology or promising students. Funds are also allocated for research projects or travel grants for young fellows.

Other activities

Funds for various activities including membership and support for the design and maintenance of the website, and the running of webinars and other e-learning.

Transfers

Transfers from unrestricted to restricted funds are made where the expenditure on projects is not covered by the income received and any shortfall must be covered by the charity.

	Balance at 1 January 2024 €	Incoming resources €	Outgoing resources €	Transfers €	Balance at 31 December 2024 €
General Unrestricted Funds	5,908,446	3,542,796	(3,441,854)	(213,463)	5,795,925
Restricted Funds					
Fellowships	-	155,000	(241,064)	86,064	-
Scholarships	26,076	-	(55,000)	28,924	-
Schools	-	512	(98,987)	98,475	-
Awards	11,385	4,000	(13,500)	-	1,885
Other activities	46,521	-	-	-	46,521
	83,982	159,512	(408,551)	213,463	48,406
TOTAL FUNDS	5,992,428	3,702,308	(3,850,405)	-	5,844,331

14. STATEMENT OF FUNDS (continued)

ANALYSIS OF NET ASSETS BY FUND

	Unrestricted 2025	**Restricted 2025**	**Total 2025**
	€	**€**	**€**
Investments	**60**	**-**	**60**
Net current assets	**5,691,630**	**21,776**	**5,713,406**
	5,691,690	**21,776**	**5,713,466**

ANALYSIS OF NET ASSETS BY FUND

	Unrestricted 2024	Restricted 2024	Total 2024
	€	€	€
Investments	60	-	60
Net current assets	5,795,865	48,406	5,844,271

15. RELATED PARTY TRANSACTIONS

In February 2024, the charitable company incorporated a limited company joint venture Jointendo Limited of 50% shareholding with the charitable company European Society of Endocrinology (Charity number 1123492). European Society for Paediatric Endocrinology paid annual congress expenditure on behalf of the joint venture totalling €103,020 (2024 –€208,618). Jointendo also committed to a gift aid donation of 50% of its profits to the charitable company totalling €1,204,068. At 31 December 2025, the joint venture owed the European Society of Paediatric Endocrinology €1,204,068 (2024 - €208,558). This balance is included within debtors due within one year.

There were no other related party transactions.

16. COMPANY LIMITED BY GUARANTEE

The company is limited by guarantee and, as such, does not have share capital. In the event of winding up, each member has guaranteed to contribute to a maximum of €10 to meet the liabilities of the company.

17. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025	2024
	€	€
Net movement in funds	**(130,865)**	(148,097)
Decrease/(increase) in debtors	**(657,687)**	307,235
Increase/(decrease) in creditors	**45,984**	250,488
Net cash used in operating activities	**(742,568)**	409,626

18. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM INVESTING ACTIVITIES

	2025	2024
	€	€
Increase in fixed asset investments	**-**	(60)
Net cash used in operating activities	**-**	(60)

19. FINANCIAL INSTRUMENTS

	2025	2024
	€	€
Financial assets		
Financial assets measured at amortised cost	**6,264,587**	5,743,685
Financial liabilities		
Financial liabilities measured at amortised cost	**389,842**	810,656

Financial assets measured at amortised cost comprise cash at bank, trade debtors, accrued income and amounts due from joint ventures.

Financial liabilities measured at amortised cost comprise other creditors and accruals.

20. EVENTS AFTER THE REPORTING PERIOD

On 17 February 2026, the charity invested a further €150k into the joint controlled entity, JointEndo Limited. This amount was matched by the other interest holder therefore the entity remained jointly controlled.

The following pages do not form part of the statutory financial statements which are the subject of the independent auditor's report on pages 21 to 23.

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

DETAILED PROFIT AND LOSS ACCOUNT

YEAR ENDED 31 DECEMBER 2025

	2025	2024
	€	€
Income		
Annual Congress income	**-**	3,329,418
Gift aid from Joint Venture	**1,204,068**	-
Fellowships:		
Clinical Fellowship	**60,000**	140,000
Research Fellowship	**-**	15,000
Scholarships:		
Visiting Professorship	**140,000**	-.
Schools:		
Summer School	**-**	-
Winter School	**-**	-
Maghreb School	**-**	-
Caucasus & Central Asia school	**-**	-
Diabetes Obesity School	**-**	-
Science School	**3,000**	512
Bone Academy	**-**	-
Awards:		
Henning Andersen Prize	**4,000**	4,000
Other activities:		
Membership	**86,780**	140,357
E-learning	**20,000**	42,500
Other	**52,273**	-
Bank interest receivable	**28,902**	30,521
	1,599,023	3,702,308
Direct costs		
Annual Congress expenditure	**97,172**	2,218,458
Society management fee	**306,398**	208,726
Fellowships:		
Clinical Fellowship	**108,672**	101,064
Research Unit	**50,000**	40,000
Research Fellowship	**264,993**	140,000
Scholarships:		
Early Career Award	**2,500**	7,500
Visiting professorship	**5,000**	15,000
Schools:		
Summer School	**125,180**	47,952
Winter School	**36,039**	13,811
Maghreb School	**35,646**	4,028
Moldova School	**4,279**	-
Bone Academy	**382**	-
Science School	**-**	-
Caucasus and Central Asia School	**9,307**	20,006
Diabetes Obesity School	**2,884**	27,362
Webinars	**2,727**	5,439
ESPE Academy	**-**	17,500
Awards:		
Andrea Prader Prize	**7,500**	7,500
Research Award	**5,000**	5,000
EU Outstanding Clinician	**-**	-
International Award	**12,000**	5,000
International Outstanding Clinician	**3,500**	-
Young Investor Award	**5,000**	5,000
Henning Andersen Prize	**4,000**	6,000
Travel Grants	**18,100**	11,839
Undergrad Achievement Award	**4,500**	2,250
	1,110,779	2,909,435
Gross surplus carried forward	**488,244**	792,873

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

DETAILED PROFIT AND LOSS ACCOUNT

YEAR ENDED 31 DECEMBER 2025

	2025	2024
	€	€
Gross surplus brought forward	**488,244**	792,873
Other activities:		
Printing and publishing	**50,679**	31,537
Website costs	**104,894**	100,976
Marketing and communication	**18,683**	8,053
Miscellaneous	**14,448**	1,331
Gross surplus	**299,540**	650,976
Governance costs:		
Bank charges	**13,037**	8,909
Council and committee meetings	**97,335**	58,994
Auditors remuneration	**43,984**	39,337
Support costs:		
Office expenses	**25,075**	37,733
Reimbursement of salary costs	**27,500**	52,708
Professional consultancy fees	**202,461**	78,287
Irrecoverable debt expense	**-**	509,739
	409,392	785,707
Operating (deficit)/surplus	**(109,854)**	(134,731)
Foreign currency (losses)/gains	**(21,011)**	(13,366)
(Deficit)/surplus on ordinary activities	**(130,865)**	(148,097)